How has been the historical performance of Windlas Biotech?

Answer:The historical performance of Windlas Biotech shows a consistent growth trajectory in net sales and profits over the years, culminating in the latest figures for March 2025.

Breakdown:
Windlas Biotech has demonstrated significant growth in net sales, increasing from 328.85 Cr in March 2020 to 759.88 Cr in March 2025. This upward trend is mirrored in total operating income, which also rose from 328.85 Cr to 759.88 Cr during the same period. The company's operating profit (PBDIT) has similarly improved, reaching 112.13 Cr in March 2025, up from 43.95 Cr in March 2020. Profit before tax has shown a steady increase, climbing from 32.14 Cr in March 2020 to 79.76 Cr in March 2025, while profit after tax reached 60.99 Cr in March 2025, compared to 16.21 Cr in March 2020. The company's total assets have expanded from 337.82 Cr in March 2020 to 760.17 Cr in March 2025, reflecting a robust growth in both current and non-current assets. Total liabilities have also increased, from 296.12 Cr in March 2020 to 760.17 Cr in March 2025, primarily driven by an increase in current liabilities. Cash flow from operating activities has fluctuated, with a notable cash flow of 68.00 Cr in March 2025, although the net cash outflow was recorded at -4.00 Cr for the same period. Overall, Windlas Biotech's financial performance indicates a strong growth trajectory with improving profitability and asset base over the years.